An overview of glucagon-like peptide-1 receptor agonists for the treatment of metabolic syndrome: A drug repositioning

Maryam Rameshrad 1, Bibi Marjan Razavi 2, 3, Jean-Daniel Lalau 4, Marc E. De Broe 5, Hossein Hosseinzadeh 3, 6

1 Natural Products and Medicinal Plants Research Center, North Khorasan University of Medical Sciences, Bojnurd, Iran
2 Targeted Drug Delivery Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
3 Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
4 Université de Picardie Jules Verne, Department of Endocrinology, Amiens, France
5 Universiteit Antwerpen, Department of Biomedical Sciences, Antwerpen, Belgium
6 Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran

ARTICLE INFO

Article type: Review article

Article history:
Received: Jul 16, 2019
Accepted: Nov 11, 2019

Keywords:
Diabetes
Dyslipidemia
GLP-1 receptor agonist
Hypertension
Metabolic syndrome
Obesity

Abstract

Metabolic syndrome (MetS) is a clustering of several cardiovascular risk factors that include: obesity, dyslipidemia, hypertension and high blood glucose, and often requires multidrug pharmacological interventions. The management of MetS therefore requires high healthcare cost, and can result in poor drug treatment compliance. Hence drug therapies that have pleiotropic beneficial effects may be of value. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are the newest anti-diabetic drugs that mimic incretin effects in the body. They appear to be safe and well tolerable. Herein, the pharmacology of GLP-1RAs, their side effects, drug interactions and their effects in MetS is assessed. We conducted a Google Scholar, PubMed, Scopus, and Web of Science search since 2010 to identify publications related to the use of GLP-1RAs in treating component features of the MetS. Keywords used for the search were: GLP-1 receptor agonist, exenatide, lixisenatide, albiglutide, dulaglutide, MetS, obesity, triglyceride, cholesterol, lipid, hypercholesterolemia, hyperlipidemia, atherosclerosis, hypertension, blood pressure, hyperglycemia, hypoglycemia and blood glucose. According to the gathered data, GLP-1RAs appear safe and well tolerated. Pre-clinical and clinical studies have evaluated the lipid-lowering, anti-atherosclerotic, anti-hypertensive and anti-diabetic effects of this class of drugs. Some these effects are related to a reduction in food-seeking behavior, an increase in atrial natriuretic peptide level and hence vascular relaxation and natriuresis, and an increase of pancreas β-cell mass and protection against glucotoxicity. Collectively, this review indicates that there may be some value in GLP-1RAs repositioning to manage MetS risk factors beyond their anti-diabetic effects.

Introduction

Incretin peptides, gastric inhibitory polypeptide (GIP) and glucagon-like peptide (GLP)-1, are secreted by the enteroendocrine cell populations known as K-cells and L cells, respectively. They stimulate pancreatic insulin secretion in response to food ingestion and enhance glucose-dependent stimulation of insulin secretion that is known as the “incretin effect” (1, 2). GIP and GLP exert their insulinotropic effects via G-protein-coupled receptors that are mainly expressed on pancreatic β cells. These receptors are also expressed in peripheral tissues and are responsible for extra pancreatic actions of incretin hormones and their metabolic effects (3). The incretin effect is responsible for 50–70% of total insulin secretion after glucose ingestion (1, 2) and is often reduced in patients with type 2 diabetes mellitus (T2DM) (4). GLP but not GIP secretion is also reduced in T2DM (4). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) with extended biological half-life have been introduced as a new class of antidiabetic drugs. The metabolic syndrome (MetS) is a clustering of metabolic disorders. It may be defined by the presence of three out of five from the following medical conditions: elevated fasting plasma glucose, abdominal obesity, elevated blood pressure, high serum triglycerides and low high-density lipoprotein (HDL) levels (5).

A growing body of evidence supports the idea that MetS is due to the combination of genetic factors (6, 7) and lifestyle factors such as diet (8) and sedentary behaviors (9). Furthermore, exposure to some chemicals (10) could increase the incidence of MetS in special occupations (11). Previous study has shown significant association of MetS with anxiety and depression (12). Excess energy intake and obesity have a pivotal role in the development of MetS components including elevated blood pressure, insulin resistance and hyperglycemia, pro-thrombotic state, pro-inflammatory state and atherogenic dyslipidemia. In this regard, non-pharmacological approaches i.e., lifestyle modification, caloric restriction are considered the primary interventions for the treatment of the syndrome (13, 14). Herbs and dietary poly phenols (9) i.e., rutin (15), black seed (16), garlic (17), grapes (18), rosemary (19), cinnamon (20), saffron (21), green tea (22), berberine...
GLP-1RAs in metabolic syndrome

(23), pepper (24), mangosteen (22) and avocado (23) may partly influence it. Besides, modification of gut microbiome by the use of prebiotics, probiotics or other dietary interventions (25) is worthwhile. However, in the case of severe obesity, bariatric surgery and drug therapies may be necessary. Depending on the individual patient's risk profile, different pharmacological drugs are prescribed in MetS (14). Since Metabolic syndrome is a multifactorial and complex disease, a combination therapy is needed to manage it. However, this kind of therapy reduces patients adherence and increases health cost and the chance of drug interactions (9). It is useful to have drugs with multiple effects, but they often are insufficiently potent to treat all the features of MetS. Recently a review has focused on DPP-4 inhibitors as a choice in managing some levels of MetS due to their polypharmacologic effects (26). However, there are limited studies on chemical drugs with pleiotropic effects for managing MetS. The aim of this study is filling this gap by introducing GLP-1RAs as a worth full drugs in metabolic syndrome that increases the number of individual targets and decreases cost and side effects of multiple therapies in this disease.

Methods

The relevant data were collected by searching the Google Scholar, PubMed, Scopus, and Web of Science. The keywords used as search terms were GLP-1 receptor agonist, exenatide, lixisenatide, albiglutide, dulaglutide, metabolic syndrome, obesity, triglyceride, cholesterol, lipid, hypercholesterolemia, hyperlipidemia, atherosclerosis, hypertension, blood pressure, hyperglycemia, hypoglycemia and blood glucose. All kinds of preclinical (in vitro, in vivo) and clinical studies that have been published since 2010 were included. Furthermore, bibliographies of eligible articles were examined for additional relevant studies. Nevertheless, congress abstracts, as well as non-English language studies, were considered ineligible for inclusion.

Based on the method, 129 appropriate articles were selected from about 750 articles that were gathered in the following main headings "pharmacology of GLP-1 receptor agonists" and "the effects of GLP-1 receptor agonists on metabolic syndrome".

Pharmacology of GLP-1 receptor agonists
Pharmacodynamics and pharmacokinetics

GLP-1 is a 30 or 31 amino acid long peptide that is processed from proglucagon (27). GLP-1 in pancreatic β-cells increases the mass and decreases apoptosis and drives insulin secretion in a glucose-dependent manner that decreases the risk of hypoglycemic episodes. It does not increase insulin secretion when the blood glucose is low. GLP-1 action on pancreatic α-cells inhibits glucagon secretion. Apartinsulinotrophic and glucagon suppressing effects, GLP-1 evokes a good control on postprandial glucose attributed to slowing gastrointestinal motility that in turn leads to delay in absorption of glucose into the circulation. Besides, by inducing central satiety, it reduces food intake and results in weight loss (28). However, the half-life of active GLP-1 is very short, 2 min, due to enzymatic degradation especially by dipeptidyl peptidase (DPP)-4 (27). According to the aforementioned data, GLP-1RAs which are resistant to degradation by DPP-4 enzyme have been developed for managing T2DM. They mimic the effects of the incretin hormone GLP-1 with longer duration action and greater potency for glucose-lowering than it. Like insulin, these drugs are given by injection. Currently available GLP-1RAs in the market are derivatives of either human GLP-1 (lixisenatide, albiglutide, and dulaglutide) or exendin-4 (exenatide, lixisenatide, and exenatide-long-acting release). Furthermore, GLP-1RAs differ with each other based on pharmacokinetic properties and pharmacodynamics profile (28, 29) (Table 1).

Long-acting GLP-1RAs with several days' half-life are prescribed weekly. They consist of albiglutide, dulaglutide, exendin-4 long-acting release (28) and recently approved ones, semaglutide (30). Short-acting forms have a plasma half-life of 2-12 h. They include exenatide, lixisenatide and lixisenatide that are managed daily (28). Of all GLP-1RAs that are prescribed subcutaneously, only semaglutide has the potential to be administered in an oral formulation. Studies on this oral agent are being evaluated (30).

Long-acting GLP-1RAs predominantly influence on both insulin and glucagon secretion that in turn regulate pre- and post-prandial glucose level. Besides, they have strong effects on fasting blood glucose. But, the short-acting agents mostly affect on the gastric emptying rate and post-prandial glucose levels (28, 29).

The efficacy of the long-acting release formulation of exenatide in the improvement of glycemic control and hemoglobin A1c (HbA1c) reduction is greater than its twice-daily formulation (31). However, lixisenatide once daily provides greater improvement in glycemic control than does once-weekly administration of exenatide (32) or albiglutide (33). Besides, comparing lixisenatide once a day with exenatide twice a day showed a significantly greater improvement in glycemic control with lixisenatide especially in obese diabetic patients.

Table 1. Comparing glucagon-like peptide-1 receptor agonists based on efficacy in glycemic control and gastrointestinal side effects

| Efficacy in glycemic control | Semaglutide (H, L) > Dulaglutide (H, L) = Liraglutide (H, S) > long-acting Exenatide (E, L) | Albiglutide (H, L) > exenatide twice daily (E, S) = Lixisenatide (E, S) |
| GI side effects | exenatide twice daily (E, S) > Lixisenatide2 (E, S) | long-acting Exenatide (E, L) > Liraglutide (H, S), Dulaglutide (H, L) > Albiglutide (H, L) |

H: a derivative of human glucagon-like peptide-1 (GLP-1); E: a derivative of exendin-4; L: long-acting GLP-1 receptor agonist with several days half life; S: short-acting GLP-1 receptor agonist with 2-12 h half life; GI: gastrointestinal

2 just in compare with exenatide twice daily but not liraglutide

Iran J Basic Med Sci, Vol. 23, No. 5, May 2020

557
time, the availability of gastric material to small intestine decreases. So, in combination therapy with other drugs, medication absorption slows, $C_{\text{max}}$ decreases and $t_{\text{max}}$ delays (45). Therefore, in combination therapy of exenatide with warfarin, warfarin dose adjustment is recommended (46). However, delaying gastric emptying time with GLP-1RAs may increase the chance of solubility and dissolution of some drugs in gastric juice that results in increased $C_{\text{max}}$ (45). This effect is seen in combination therapy of liraglutide with griseofulvin (47). Totally, GLP-1RAs-drug interactions are important with drugs that require a rapid start of action or those need to reach a suitable concentration peak (45).

### The effects of GLP-1 receptor agonists on metabolic syndrome

**Effects on lipid profile, body weight and related complications**

Atherosgenic dyslipidemia is defined as the elevation of low-density lipoprotein (LDL-C) and non-HDL-C accompanied by the decrease of HDL-C. This condition results in atherosclerosis and cardiovascular diseases. Insulin resistance, obesity, and related inflammatory conditions are associated with atherosogenic dyslipidemia and atherosclerosis (5, 48). Obesity and dyslipidemia are the main predisposing factors for MetS. Incretin-based therapy is now considered as a new approach to treating obesity (2, 49) concurrently with diabetes (50) or associated with hypothalamic disorders (51). Proposed mechanisms in this field are their involvement in both peripheral (vagal and central (hindbrain and hypothalamus) pathways mediating satiety (52, 53) and also decrease in the food-induced reward signals and so decline of food-seeking behavior (53). In obesity and diabetes, glucose-dependent insulinotropic peptide (GIP)/GIPR and GLP-1 signaling are impaired. Restoring this damage results in a potential therapy for these diseases (52, 54, 55). Furthermore, their anti-obesity and glucose regulatory effects are linked to up-regulation of irisin, and so increase of muscle metabolism via AMPK-activated protein kinase (AMPK) pathway (56). In the following some of the related studies are explained (Table 2).

### Preclinical studies

Liraglutide possesses anti-atherogenic effects by suppressing macrophages foam cells formation related to blocking acyl-CoA: cholesterol acyltransferase 1 (57).

Lixisenatide, the other GLP-1 analogue, by modulating STAT signaling pathway leads reprogramming of macrophages towards an M2 phenotype, decreases pro-inflammatory cytokine secretion and in turn reduces the atheroma plaque size and related cardiovascular events (58).

Liraglutide attenuated a high-fat diet-induced atherosclerosis in apo E–/– mice. In rat VSMCs culture, liraglutide inhibited angiotensin II-induced cell proliferation linked to activation of AMPK and in turn cell cycle arrest in G0/G1 phase (59). The blocking of GLP-1 signaling results in obesity in rats via decrease of nutrient-induced satiation (60). Over-expressing of GIP in mice improved insulin sensitivity, glucose tolerance, β cell function and reduced energy intake. Animals

(34). Administration of lixisenatide once daily is not superior to exenatide twice daily in HbA1c reduction (35). Besides, once-weekly dulaglutide has no greater reduction in HbA1c in comparison with once-daily liraglutide (36). Semaglutide efficacy in controlling glycemia and body weight is greater than the other GLP-1RAs of exenatide releases and dulaglutide (37)(Table 1).

Pharmacogenetic studies on GLP-1R agonists should be considered. The presence of naturally occurring nonsynonymous single nucleotide polymorphisms on GLP-1 gene, evokes multiple complexity and effect on the pharmacological impact of GLP-1RAs. Some introduced human GLP-1R single nucleotide polymorphisms are as follow: substitution of Leu for Pro at position 7 (rs10305420), substitution of Lys for Arg at position 20 (rs10305421), substitution of His for Arg at position 44 (rs2295006), substitution of Gly for Arg at position 131 (rs3765467), substitution of Met for Thr at position 149 (rs112198), substitution of Ser for Gly at position 168 (rs6923761), substitution of Leu for Phe at position 260 (rs1042044), substitution of Thr for Ala at position 316 (rs10305492), substitution of Cys for Ser at position 333 (rs10305493), and substitution of Gln for Arg at position 421 (rs10305510). Rs10305493 variant preserves the function of GLP-1R (38). However, Rs367543060 variant dramatically decreases the peptide response (38, 39). In non-diabetic volunteers, rs6923761 variant, the substitution of serine for glycine at position 168, decreases insulinitropic responses to GLP-1 infusion in hyperglycemic condition (40). In contrast, this polymorphism increases the efficacy of liraglutide on weight loss and metabolic improvement in diabetic patients (41).

### Side effects

Comparing with long-acting exenatide, mild nausea, vomiting, upper respiratory tract infections and injection site bruising are more frequent with that twice a day. Injection site pruritus with a mild intensity that is resolved with continued treatment and constipation is seen with long-acting exenatide (31). Besides, the frequencies of gastrointestinal disturbances (nausea, diarrhea, and vomiting) with the long-acting formulation of exenatide are greater than liraglutide (32). Both liraglutide (34) and lixisenatide (35) are well tolerable than exenatide twice daily formulation. Compare with albiglutide, the rate of nausea and vomiting is lower and injection-site reactions are greater than liraglutide (33). The tolerability of dulaglutide and liraglutide seems to be the same (36)(Table 1).

Totally, all GLP-1RAs are well tolerable and incidence of adverse effects is low. Gastrointestinal problems and nausea are the most commonly reported complications with them that are minimized by gradual dose titration. In exenatide-treated patients, anti-exenatide antibody formation has been reported (42). Pancreatitis and pancreatic cancer, thyroid C cell tumors, gallbladder-related adverse events (43) and retinopathy (with semaglutide) (30, 44) are the other concern about GLP-1RAs that further studies should determine them.

### Drug interactions

Since this class of drugs prolongs the gastric emptying process, the availability of gastric material to small intestine decreases. So, in combination therapy with other drugs, medication absorption slows, $C_{\text{max}}$ decreases and $t_{\text{max}}$ delays (45). Therefore, in combination therapy of exenatide with warfarin, warfarin dose adjustment is recommended (46). However, delaying gastric emptying time with GLP-1RAs may increase the chance of solubility and dissolution of some drugs in gastric juice that results in increased $C_{\text{max}}$ (45). This effect is seen in combination therapy of liraglutide with griseofulvin (47). Totally, GLP-1RAs-drug interactions are important with drugs that require a rapid start of action or those need to reach a suitable concentration peak (45).
Table 2. The effects of glucagon-like peptide-1 receptor agonists on lipid profile, body weight and related complications

| Study Type | Condition | Treatment | Outcome (some concentrations) |
|------------|-----------|-----------|-------------------------------|
| In vitro studies | Primary cultured human monocyte-derived macrophages | GLP-1 (0.5-10 nM), GIP (0.5-10 nM), exendin (10-150 nM) or liraglutide (10-150 nM) | ↓ cholesterol ester accumulation, ↓ ACAT1 expression, ↑ ABCA1 expression, ↓ CD36 expression (but not with liraglutide) |
| | Murine bone-marrow-derived macrophages | Lixisenatide 40 nM for 7 days, LPS 100 ng/ml for the last 24 h or 6 hr | ↓ IL-6 secretion in the supernatant stimulation with LPS for 6 hr: ↓ pSTAT1/STAT1, ↑ pSTAT3/STAT3, ↓ iNOS/α-tubulin (M1 macrophage marker) stimulated with LPS for 24 h: ↑ arginase I/α-tubulin (M2 macrophage marker) |
| | Pre adipocyte 3T3-Li cells | Liraglutide (10, 100 µM) for 3 days | ↓ size of droplet after 10 days, ↑ all brown fat markers examined, including Cidea, PPARγ, PRDM16, and UCP-1, as well as mitochondrial markers (CytoC1, PGC1α, TFAM) and COX-IV |
| Animal studies | Male apo E−/− mice on high-fat diet | Liraglutide 107 nmol/kg/day, for 4 weeks | ↓ body weight, ↑ GLP-1, ↓ surface area of atherosclerosis lesions in aorta, ↓ monocyte/macrophage accumulation in aorta |
| | Apo E−/− mice on atherogenic diet for 2 months | Lixisenatide, 10 µg/kg/day or liraglutide 400 µg/kg/day, during the last month of diet | ↓ blood pressure, ↓ fasting plasma insulin, improved glucose metabolism, ↓ atherosclerotic lesions in aortic arch, ↓ macrophages, T-lymphocytes, collagen area and, necrotic core in atheroma, ↓ fibrosis cap thickness in the atheroma area, ↓ circulating plasma level of IL-6, ↑ arginase I in plaques (M2 macrophage marker), ↓ iNOS in plaques (M1 macrophages marker), ↑ arginase I/NO-stained area in atheroma |
| | Apo E−/− mice on high-fat diet | Liraglutide, 400 mcg/day for 4 weeks | in the aortic wall: ↓ atherosclerotic lesions, ↑ AMPK activation, ↑ relaxation responses to acetylcholine |
| | Female Sprague-Dawley rats on high-fat diet for 6 weeks, prior to pregnancy, during pregnancy and lactation, then their offspring were weaned to high-fat diet | Exendin | in the kidneys: ↓ inflammation, ↓ oxidative stress, ↓ fibrosis |
| | Male Swiss mice on high-fat diet for 20 weeks | Liraglutide, 200 µg/kg, BID, for 28 days | ↓ body weight, ↓ energy intake, improving non fasting glucose normalization, glucose tolerance test, ↑ recognition index, ↑ learning and memory ability |
| | UC Davis Type 2 Diabetes Mellitus (UCD-T2DM) rat | Liraglutide 0.2 mg/kg, BID, 4 months | the onset of diabetes was delayed, ↓ diabetes incidence, ↓ non-fasting blood glucose, ↓ FBS, ↓ HbA1c, ↓ body fat, ↓ lean body mass, ↓ body ash, ↓ plasma insulin, ↓ body weight, ↓ energy intake, ↓ glycosuria, ↓ albuminuria, ↓ 24 hr urine volume, ↓ triglyceride, ↑ adiponectin |

References:
(57) Rameshrad et al. Iran J Basic Med Sci, Vol. 23, No. 5, May 2020, p. 559
Continued Table 2

| Treatment Description | Outcome Measures |
|-----------------------|------------------|
| High-fat diet induced diabetes and obesity in db/db and C57BL/6j mice, respectively | ↓ body weight | (66) |
| Liraglutide 0.2 mg/kg/day, for 12 weeks | ↓ HOMA-IR | (66) |
| | ↑ hepatic adenylate cyclase 3 | |
| High-fat diet induced obesity in KKAY mice | ↓ body weight | (67) |
| Liraglutide 400 µg/kg/day, for 12 weeks | ↓ adipocyte size in white fat | (67) |
| | ↓ the white fat browning | (67) |
| | ↑ mitochondrial biogenesis in white fat | (67) |
| | ↑ soluble guanylate cyclase-dependent pathway | (67) |
| High-fat diet induced obesity in rats | ↓ body weight | (68) |
| Exenatide, 10 µg/kg, for one month | ↓ FBS | (68) |
| | ↓ insulin level | (68) |
| | ↓ insulin resistance | (68) |
| | ↓ dyslipidemia | (68) |
| | ↓ oxidative stress | (68) |
| | ↓ TNF-α; serum level | (68) |
| | ↑ hypothalamic insulin receptor | (68) |

Clinical study

| T2DM<sup>23</sup> on a weight-maintaining diet, 3 weeks before the study | ↓ hepatic fat content | (62) |
| Exenatide 5-10 µg, BID and pioglitazone 30-45 mg/day orally for 52 weeks | ↓ plasma FGF21<sup>24</sup> concentration | |
| Children and adolescents (age 9-16 years old) with extreme obesity | ↓ BMI<sup>24</sup> | (71) |
| Exenatide 5-10 µg, BID, for 3 months | ↓ body weight | (71) |
| | ↓ fasting insulin | (71) |
| | improved OGTT<sup>25</sup> and β ano function | |
| Obese T2DM patients | ↓ body weight | (72) |
| Liraglutide 0.6-1.2 mg/day, for 12 weeks | ↓ daily insulin dose | (72) |
| | ↓ hypoglycemic events | (72) |
| | ↓ body weight and waist circumference | (72) |
| Patients with hypothalamic obesity | ↓ body weight but not significantly | (75) |
| Exenatide 10 µg, BID, for 52 weeks | |
| T2DM patients with obesity, progressive weight gain, and insufficiently glycemic control on insulin therapy | ↓ body weight | (77) |
| Exenatide 5 µg, BID, for 12 months | ↓ insulin doses | (77) |
| T2DM uncontrolled on oral antidiabetic drugs | ↓ HbA1c | (78) |
| Exenatide, for 26 weeks | ↓ weight | (78) |
| | ↓ epicardial adipose tissue | (78) |
| | ↓ hepatic triglyceride content | (78) |
| T2DM with obesity | ↑ irisin | (56) |
| Exenatide, for 12 weeks | ↓ FBS | (56) |
| | ↓ HbA1c | (56) |
| | ↓ BMI | (56) |
| Adults 18 years or older, obesity class I and II | delayed the gastric emptying of solids | (79) |
| Exenatide 5 µg, BID, for 30 days | ↓ weight loss (not significant) | (79) |
| | ↓ apnea-hypopnea index | (83) |
| Non-diabetic participants with obesity with moderate to severe obstructive sleep apnea | ↓ weight | (83) |
| Liraglutide 3.0 mg, 32 weeks both as adjunct to diet (500 kcal<sup>26</sup> day -1 deficit) and exercise | ↓ HbA1c | (83) |
| | ↓ systolic blood pressure | (83) |
| Overweight and obese elderly with T2DM | ↓ body mass index | (84) |
| Liraglutide up to 3 mg/day for 24 weeks | ↓ weight | (84) |
| | ↓ fat mass | (84) |
| | ↑ glycemic control | (84) |
| | ↑ skeletal muscle index | (84) |
| T2DM patients | ↓ postprandial triglyceride, apoB48 and glucose | (85) |
| Liraglutide 1.8 mg/day, for 21 days | ↑ postprandial insulin and C-peptide | (85) |
| | ↓ FBS | (85) |
| | ↑ fasting insulin | (85) |
| | ↑ fasting C-peptide | (85) |
| T1DM on insulin and sub-optimal glycaemic control or obesity | ↓ HbA<sub>1c</sub> | (87) |
| A GLP-1 analogue was added to pre-existing treatment | ↓ weight | (87) |

1 Glucagon like peptide; 2 Gastric inhibitory polypeptide; 3 Acetyl-CoA acetyltransferase; 4 Interleukin 6; 5 Signal transducer and activator of transcription; 6 Inducible nitric oxide synthase; 7 Lipopolysaccharide; 8 Peroxisome proliferator-activated receptor gamma; 9 PR domain containing 16; 10 Mitochondrial uncoupling proteins; 11 c/yc; 12 Peroxisome proliferator-activated receptor-gamma coactivator; 13 Mitochondrial transcription factor A; 14 Cytochrome c oxidase subunit 4; 15 Irs2; 16 S adenosine monophosphate-activated protein kinase; 17 BID; 18 Fast blood sugar; 19 Hemoglobin A1c; 20 Homeostatic model assessment for insulin resistance; 21 Tumor necrosis factor-α; 22 Type 2 diabetes mellitus; 23 Fibroblast growth factor 21; 24 Body mass index; 25 Oral glucose tolerance test; 26 Kilocalorie
showed less weight gain and adiposity in response to high-fat diet (61).

According to a study on diet-induced obesity in mice, administration of exendin-4 resulted in improving effects attributed to the decrease in hepatic fibroblast growth factor 21 resistances. It is good to mention that hepatic fibroblast growth factor 21 evokes an important role in increasing insulin sensitivity, reducing triacylglycerol levels and hepatic steatosis, and improving glucose tolerance (62). Besides, exendin-4 evoked protective effects against maternal obesity-induced renal dysfunction in offsprings (63).

Liraglutide administration to hyperlipidemic mice improved metabolic disorders, body weight as well as memory and learning (64). Besides, its chronic administration delayed the onset of diabetes and diabetes-related metabolic disorders including dyslipidemia, insulin resistance and weight gain (65). Liraglutide restored body weight as well as HOMA-IR (Insulin resistance index) via up-regulation of hepatic adenylate cyclase 3 level (66). It has been shown that liraglutide induces its beneficial effects on metabolism by driving white adipose tissue phenotype to brown phenotype via soluble guanylate cyclase-mediated pathway (67).

Exenatide induces anti-inflammatory and anti-oxidant effects in high-fat-diet-induced obesity in rats. It evoked regulatory effects on fasting blood sugar (FBS), lipid profile, and induced weight loss. The beneficial effects of this drug were linked to up-regulation of hypothalamic insulin receptors. These receptors regulate appetite, white fat mass metabolism, and hepatic glucose output (68).

Clinical studies
Prediabetes, T2DM, obese or overweighted individuals have lower GLP-1 responses to an oral glucose tolerance test (69). In a patient with Prader-Willi syndrome, who had been insufficiently controlled with insulin therapy, adding exenatide improved glycaemia, reduced weight gain and restored blood pressure, microalbuminuria, glycosylated hemoglobin and lipid profile (70). Besides, exenatide efficacy on lipid profile (62) and extreme obesity in pediatrics (71) has been proven in another studies.

In comparison with increasing insulin doses, adding liraglutide to obese T2DM patients not only had a good glycemic control but also possessed good effects on the control of body weight gain (72).

GLP-1 agonists, exenatide or liraglutide, could be engaged as an important modulatory therapy in patients with morbid hypothalamic obesity by controlling appetite (73-75). Folli and Mendoza (2011) have reviewed the potential effects of exenatide for the treatment of obesity. According to the literate data, in obese patients with/without T2DM, administration of exenatide decreased body weight, improved glycemic control and reduced blood pressure and body fat mass (76). It has promising effects in T2DM patients who suffered from weight gain and had insufficiently glycemic control on insulin therapy (77). Exenatide has been proposed as a good treatment in the reduction of liver and epicardial fat content in obese patients with T2DM (78). The beneficial effects of exenatide treatment on the decrease of body weight and restoration of FBS and HbA1c in T2DM patient were linked to up-regulation of irisin (56) and delay in the gastric emptying time (79). It had been discussed that irisin has a fundamental role in glucose metabolism by stimulating membrane translocation of glucose transporter type 4 and AMPK phosphorylation (80). Besides, exenatide treatment reduces bone morphogenetic protein-4 level that is a regulator of white adipogenesis, independently to weight loss (81).

In comparison with orlistat, liraglutide is a valuable option to improve the success of weight loss in obese and overweight individuals without diabetes (82). Administration of liraglutide to obese and non-diabetic patients with sleep apneaa, decreased apneaa in relation to reduction of body weight (83). Besides, it showed a good efficacy in reducing body mass index and fat mass with increase in skeletal muscle index in overweight and obese T2DM patients (84) and improvement of postprandial lipaemia in T2DM patients independently to gastric emptying (85). Not only in adult patients, but also in adolescents, liraglutide administration had good impacts in controlling obesity with similar safety and tolerability (86).

Administration of GLP-1 agonists not only in T2DM but also in type 1 diabetes mellitus, evokes worth effects in glycemic control and decreasing body weight (87).

According to the clinical data, the combination therapy of metformin plus exenatide is a worth therapy for reducing intra-abdominal fat content and inflammatory states and restoring insulin resistance in obese patients with T2DM (88). Surprisingly, this combination therapy is more effective in overweight and obese women than in men patients (89).

Furthermore, a meta-analysis of randomized controlled trials study have proved the efficacy of GLP-1RAs in decreasing C-reactive protein, an inflammatory marker, in patients with T2DM (90).

Effects on the high blood pressure
GLP-1RAs that are used to treat T2DM have beneficial effects on the cardiovascular system in chronic exposure. Minor rise in blood pressure and heart rate that is seen in short-term exposure with these agents is linked to CNS pathways. However, after intermediate- or long-term exposure these effects are compensated. Totally, anti-hypertensive effects of GLP-1RAs is classified into renal- and non-renal-mediated mechanisms. GLP-1RAs increase atrial natriuretic peptide (ANP) level by effects on atrial cardionocytes that in turn evokes cyclic guanosine monophosphate and NO production and hence vascular relaxation. Besides, ANP elevation promotes sodium excretion and natriuresis. A decrease in the plasma renin activity is the other proposed mechanisms. Furthermore, the decrease in blood presser with this class is considered as an outcome of weight loss, inhibition of intestinal salt absorption, central inhibition of salt intake, endothelial-dependent vasodilation and direct action on vascular smooth muscles (91, 92). In the following some of the related studies are explained (Table 3).

Preclinical studies
GLP-1RAs are associated with a modest reduction in
Table 3. The effects of glucagon-like peptide-1 receptor agonists on the high blood pressure

| Study design | Results | Ref. |
|--------------|---------|------|
| Animal study | | |
| Dahl salt-sensitive rats were fed with high-salt chow and AC3174, SC\(^1\) infusion, or GLP-1\(^2\), 4 weeks | ↓ SBP\(^3\), ↓ left ventricular wall stress, ↓ left ventricular mass and serum creatinine (just with AC3174), ↓ fasting insulin, ↓ HOMA\(^4\) index, ↑ creatinine clearance rate, improvement of high salt diet-renal sclerosis (94) | |
| Pre-pubertal female Sprague Dawley rats between 4-5 weeks of age implanted S.C. with DHT\(^5\) pellets (90 day release; 83μg/day), after 12 weeks of age, received liraglutide 0.2 mg/kg, S.C., BID\(^6\) for 4 weeks | ↓ body weight, improved glucose tolerance test, improved mean arterial pressure (95) | |
| GLP-1\(^r\)-/\(^m\) mice: Ang II, S.C., for 3 weeks followed by liraglutide | no effects on systolic or diastolic blood pressure, no effects on the plasma ANP\(^8\) concentration | |
| isolated mice heart | liraglutide has no effects on concentration of ANP in heart perfusate (97) | |
| NPPa\(-\)/\(\)-mice (ANP knockout): Ang II, S.C., for 3 weeks followed by liraglutide | liraglutide has no effects on blood pressure and sodium/creatinine in urine | |
| wild type mice: Ang II, for 3 weeks followed by liraglutide, | ↑ plasma ANP concentration | |
| Exendin\(^9\)-39 (a GLP-1R antagonist), or L-NMMA\(^9\) or anantin\(^10\) for 2 days, followed by liraglutide, in isolated aorta pre-contracted with phenylephrine, Ach\(^11\): produced dose dependent relaxation, ↑ p-eNOS, vasodilator stimulated phosphoprotein and cGMP\(^12\) in aorta | liraglutide had none of aforementioned effects | |
| Clinical studies | | |
| T2DM\(^16\): Exenatide, 5 µg for 4 weeks followed by 10 µg, BID for 12 weeks, S.C. | liraglutide increased concentration of ANP in perfusate, a slight but not significant decreasing effects on SBP (98) | |
| T2DM: PF-04603629, 1, 3, 10, 20, 40, 50 and 70 mg, single dose, S.C. | after 24 hr a dose related but not significant increasing effects on pulse rate and DBP\(^13\) | |
| T2DM: Liraglutide 0.6, 1.2 or 1.8 mg single dose with metformin | ↓ HbA1c\(^14\), ↓ FBG\(^15\), ↓ PPG\(^16\), ↓ body weight, ↓ hypoglycemia episodes ↓ SBP (102) | |
| T2DM and peritoneal dialysis: Liraglutide for 12 months | ↓ HbA1c, ↓ glycosylated albumin, ↓ fasting/postprandial glucose level, ↓ daily glucose level, ↓ glycemic fluctuation, ↓ SBP, ↓ left ventricular mass index, ↑ left ventricular ejection pressure, ↑ diurnal and nocturnal SBP and pulse pressure, ↑ diurnal and nocturnal heart rate (108) | |
| T2DM and HTN\(^17\): Dulaglutide, 1.5 or 0.75 mg, single a week, for 26 week, S.C. | | |

1 Subcutaneous injection; 2 Glucagon-like peptide-1; 3 Systolic blood pressure; 4 Homeostatic model assessment; 5 Dihydrotestosterone; 6 Two times a day; 7 Angiotensin II; 8 Atrial natriuretic peptide; 9 A nitric oxide synthase inhibitor; 10 A natriuretic peptide receptor antagonist; 11 Acetylcholine; 12 Cyclic guanosine monophosphate; 13 Diastolic blood pressure; 14 Hemoglobin A1c; 15 Fast blood glucose; 16 Post prandial glucose; 17 Hypertension; 18 Type 2 diabetes mellitus
blood pressure and a slight increase in heart rate, but no significant association with hypertension (93). AC3174, the exenatide analogue, better than GLP-1 evoked anti-hypertensive, cardio protective and renoprotective as well as insulin-sensitizing effects in Dahl salt-sensitive rats. It has been proposed as a good choice for increasing survival in cardiorenal syndrome and hypertension (94). Liraglutide administration is a valuable engaged therapy in T2DM, hypertension associated with polycystic ovary syndrome (95) and pulmonary hypertension (96).

In vitro and mice studies revealed that the hypotensive effects of liraglutide are a GLP-1 and ANP mediated mechanisms. It has been verified that gut GLP-1 by influence on atrial GLP-1 receptors directly enhances cardiac ANP secretion and in turn relaxes vascular tone and indirectly increases sodium/creatinine urine excretion and so evokes hypotension (97).

Clinical studies

Some clinical studies proposed the modulatory effects of exenatide on systolic blood pressure, especially in patients with T2DM and hypertension (98, 99). However, a single dose administration of PF-04603629, a long-acting GLP-1 mimic compound, increased pulse rate and mean diastolic blood pressure that not exceed from normal range (100). One clinical study on healthy volunteers verified that intestinal glucose load possesses hypotensive potential effects by influence on GLP-1 release (101). In comparison with glimepiride, treatment with liraglutide is superior especially in T2DM patients with weight gain, hypoglycemic episodes, and hypertension (102).

Based on a clinical study, the blood pressure-lowering effects of exenatide have been attributed to its effects on glycaemia and body weight (103), where the later study excluded its relation with weight loss or improvement in Hba1c (104).

Systematic and meta-analysis verified the blood pressure (104-107) and weight (104, 106) lowering effects of liraglutide and exenatide in T2DM patients. Besides, it has been confirmed that GLP-1 consumption is associated with the rise in heart rate (104, 106) and in compare with exenatide, heart rate rises were greater with liraglutide (106). The safety and efficacy of liraglutide in T2DM patients who are on peritoneal dialysis have been proved in controlling glucose levels, glycemic fluctuations, blood pressure and improving left ventricular functions (108). The efficacy of 36-month liraglutide therapy has been evaluated in a retrospective study on T2DM patients. Based on the gathered data, liraglutide had preserved its effects on controlling body weight, metabolic factors, LDL, blood pressure and waist circumference after 3 years. Besides, it had no major effects on heart rate and renal parameters (109). Furthermore, in chronic heart failure patients without T2DM, administration of liraglutide reduced body weight, Hba1c and 2-hr glucose tolerance test with no effects on myocardial glucose uptake, myocardial blood flow, and myocardial blood flow reserve (110). The other clinical study on T2DM patients with stable coronary artery disease monitored the effects of liraglutide on 24 hr ambulatory blood pressure and showed it has no blood pressure lowering effects but enhances 24 hr heart rate (111).

Administration of dulaglutide to hypertensive T2DM patients is accompanied by the decrease of systolic blood pressure and pulse pressure and rise of heart rate (112). According to a clinical data on well-controlled T2DM patients, the intravenous administration of exenatide is accompanied by the increase of heart rate and mean atrial pressure during intraduodenal infusion of glucose (113).

Effects on the serum glucose level

GLP-1RAs are the newest class of anti-diabetic agents. So many studies have proved their effectiveness in this field. Herein, we mainly notice mechanistically to their superior effects in glycemic control. Both GLP-1 analogues and DPP-4 inhibitors reduce Hba1c. However, GLP-1 analogues are more effective in weight loss and glycemic lowering (114). Administration of GLP-1 analogues with basal insulin addresses beneficial effects in T2DM patients who are overweight and uncontrolled on oral anti-diabetic drugs or basal insulin (115). GLP-1RAs promote autophagy by modulating AMPK activity that leads to reserve pancreas β-cell mass and its protection against glucotoxicity (116). It has been proved that delayed timing of post-challenge peak glucose relates with deteriorating pancreas β-cell function and worsening oral glucose tolerance test. Liraglutide by increasing pancreas β-cell function improves oral glucose tolerance test and shifts the timing of peak serum glucose earlier (117).

Administration of liraglutide (1.2 mg/day for 6 months) decreases body weight, Hba1c and liver fat content (118).

In comparison with patients treated with basal insulin, exenatide administration results in similar glycemic control with greater weight reduction (119). GLP-1 agonists cause in a good control on postprandial glucose level. Exenatide administration to metformin-treated T2DM patients improved daily glucose control, FBS and postprandial glucose level (120). This drug by decreasing the gastric emptying rate has an important role in postprandial plasma glucose level (121).

Semaglutide significantly restores lipid metabolism, fasting, and postprandial glucose level. Although the gastric emptying rate is totally similar between semaglutide and placebo, the first-hr delay with this drug may decrease the rate of glucose entry into the circulation (122). Furthermore, the addition of lixisenatide, a short-acting GLP-1 agonist, to insulin-treated T2DM patients leads a good control on Hba1c levels by slowing gastric emptying and reducing postprandial glucose excursions (123).

In insulin-treated T2DM patients on hemodialysis, dulaglutide improved glycemic control and evoked a decrease in insulin daily dose (124). Administration of dulaglutide was accompanied by the reduction of body weight, especially in women. Although it restored Hba1c and FBS level without regard to gender, greater reduction in Hba1c and FBS level and modest hypoglycemia incidence had been seen in patients with a higher Hba1c baseline (125). It is important to consider that chronic administration of liraglutide to healthy volunteer does not result in tolerance to its
glucose-lowering effects (126).

**Discussion**

Nowadays, metabolic syndrome and its associated complications are considered as the most important health problem worldwide. It is estimated to affect over a billion people in the world (127), hence it imposes great healthcare burden globally. Lifestyle modification and caloric restriction remain the primary tools for managing its predisposing disorders including dyslipidemia and insulin resistance(13, 14). However, in severe conditions, pharmacological interventions may be required to control lipid abnormalities, hypertension and glucose intolerances in which a large number of pharmacological options are present. In this regard, DPP-4 inhibitors, sodium-glucose cotransporter 2 inhibitors, and GLP-1 receptor agonists are proposed for glucose-lowering medications. Orlistat, phentermine/topiramate, lorcaserin, naltrexone sustained release/ buPROPion sustained release and liQaglutide are suggested for body weight reduction. This kind of combination therapy imposes great health-cost, increases the possibility of drug interactions and related side effects, and therefore decreases patients’ compliance (9). Introducing pleiotropic drugs that control all aspects of metabolic syndrome as a single disease is a key area for improvement in managing MetS and increasing patients’ compliance. To the best of our knowledge, there is a gap in introducing and approving polypharmacological drugs that manage MetS as a whole.

Drug discovery in traditional drug development usually takes 10-15 years and the success rate is very low. Furthermore, it needs high investments and is very expensive. Drug repositioning that becomes popular in recent years involves investigating and approving new therapeutic uses for old drugs. In comparison with drug discovery, drug repositioning is an efficient, economical and riskless process (128).

The drug repositioning strategy includes three steps. First, the identification of an appropriate drug for the diseases; then, mechanistic evaluation of its effect in preclinical studies; and finally, efficacy assessment in phase II clinical trials. Of these three steps, step 1 “finding novel drug-disease relationships” is the gold matter in the drug repositioning (129).

GLP-1RAs are one of the newest pharmacological interventions in managing diabetes with great glycemic control especially in overweight T2DM patients who are uncontrolled with the other anti-diabetic drugs. According to both preclinical (in vitro and animal) and clinical studies, GLP-1RAs by effects on peripheral and central pathways induce satiety, decrease body weight and control dyslipidemia. They induce p-AMPK activation, decrease pro-inflammatory conditions and evoke anti-atherogenic effects. Chronic administration of GLP-1RAs overcome hypertension by renal- and non-renal mediated mechanisms. (Figure 1). However, these effects are modest and limited to some levels.

Herein, we proved our hypothesis “the effectiveness of GLP-1RAs in MetS”, showed this relation and solved the first step of drug repositioning. In the future, long-term randomized clinical trial results are needed to validate these preliminary data, and post-marketing evaluation is necessary to verify their safety, especially during pregnancy, breastfeeding, and susceptible people. Furthermore, reformulation and synthetization newly design chemicals of GLP-1RAs and/or combination with other drug/s might improve their efficacy on MetS components. Approving and adding this kind of drugs as an adjuvant or main therapy to therapeutic guidelines decrease side effects and the risk of drug interactions, and increase patients’ compliances. This category of pharmacological drugs, GLP-1RAs, may reach researchers of MetS to their ultimate goal: managing MetS as a single disease. It seems hard but not impossible to develop new drugs with polypharmacological effects on MetS component as a single condition in the future.

**Acknowledgment**

This work was supported by North Khorasan University of Medical Sciences, Clinical Research Development Units, Bojnurd, Iran and Mashhad University of Medical Sciences, Mashhad, Iran. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Conflicts of Interest**

The authors declare that there are no conflicts of interest.

**References**

1. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132:2131-2157.
2. Barber TM, Begbie H, Levy J. The incretin pathway as a new therapeutic target for obesity. Maturitas 2010; 67:197-202.
3. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 2013; 17:819-837.
4. Bagger JI, Knop FK, Lund A, Vestergaard H, Holst JJ, Vilsboll
IRAN J BASIC MED SCI, VOL. 23, NO. 5, MAY 2020

T. Impaired regulation of the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab 2011; 96:737-745.
5. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112:2735-2752.
6. Masoudi-Kazemabad A, Jamialahmadi K, Moohabati M, Mojarrad M, Manshadi RD, Aldlaghi S, et al. Neuropeptide y Leu7Pro polymorphism associated with the metabolic syndrome and its features in patients with coronary artery disease. Angiology 2013; 64:40-45.
7. Azimi-Nezhad M, Mirhafiz SR, Stathopoulou MG, Murray H, Ndiaye NC, Bahrami A, et al. The relationship between vascular endothelial growth factor Cis- and trans-acting genetic variants and metabolic syndrome. Am J Med Sci 2018; 355:559-565.
8. Khayatzadeh SS, Moohabati M, Mazidi M, Avan A, Tayefi M, Parizadeh SMR, et al. Nutrient patterns and their relationship to metabolic syndrome in Iranian adults. Eur J Clin Invest 2016; 46:840-852.
9. Rask Larsen J, Dima L, Correll CU, Manu P. The pharmacological management of metabolic syndrome. Expert Rev Clin Pharmacol 2019; 11:397-410.
10. Stojanoska MM, Milesovic N, Milic N, Abenavoli L. The influence of phthalates and bisphenol A on the obesity development and glucose metabolism disorders. Endocrine 2017; 55:666-681.
11. Baghshini MR, Nikbakht-Jam I, Mohaddes-Ardabili H, Pasdar A, Avan A, Tayefi M, et al. Higher prevalence of metabolic syndrome among male employees of a gas refinery than in their counterparts in nonindustrial environments. Asian Biomed 2017; 11:227-234.
12. Bagheriniya M, Khayatzadeh SS, Avan A, Safarian M, Nemati M, Ferns GA, et al. Metabolic syndrome and its components are related to psychological disorders: A population based study. Diabet Metab Syndr 2017; 11:S561-S566.
13. Cornier M-A, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, et al. The metabolic syndrome. Endocr Rev 2008; 29:777-822.
14. Grundy SM. Metabolic syndrome update. Trends Cardiovasc Med 2016; 26:364-373.
15. Hosseinzadeh H, Nassiri-Ash M. Review of the protective effects of rutin on the metabolic function as an important dietary flavonoid. J Endocrinol Invest 2014; 37:783-788.
16. Razavi BM, Hosseinzadeh H. A review of the effects of *Nigella sativa* L. and its constituent, thymoquinone, in metabolic syndrome. J Endocrinol Invest 2014; 37:1031-1040.
17. Hassani FV, Shirani K, Hosseinzadeh H. A review on the effects of *Allium sativum* (Garlic) in metabolic syndrome. J Endocrinol Invest 2015; 38:1147-1157.
18. Akaberi M, Hosseinzadeh H. Grapes (*Vitis vinifera*) as a potential candidate for the therapy of the metabolic syndrome. Phytother Res 2016; 30:540-556.
19. Hassan FV, Shiri M, Hosseinzadeh H, Rosemary (*Rosmarinus officinalis*) as a potential therapeutic plant in metabolic syndrome: a review. Naunyn Schmiedebergs Arch Pharmacol 2016; 389:931-949.
20. Mollazadeh H, Hosseinzadeh H. Cinnamon effects on metabolic syndrome: A review based on its mechanisms. Iran J Basic Med Sci 2016; 19:1258-1270.
21. Razavi BM, Hosseinzadeh H. Saffron: a promising natural medicine in the treatment of metabolic syndrome. J Sci Food Agric 2017; 97:1679-1685.
22. Toussian Shandiz H, Razavi BM, Hosseinzadeh H. Review of *Garcinia mangostana* and its xanthones in metabolic syndrome and related complications. Phytother Res 2017; 31:1173-1182.
23. Tabeshpour J, Razavi BM, Hosseinzadeh H. Effects of avocado (*Persea americana*) on metabolic syndrome: A comprehensive systematic review. Phytother Res 2017; 31:819-837.
24. Sanati S, Razavi BM, Hosseinzadeh H. A review of the effects of *Capsicum annuum* L. And its constituent, capsaimin, in metabolic syndrome. Iran J Basic Med Sci 2018; 21:439-448.
25. Mazidi M, Rezaie P, Kengne AP, Mobaran MG, Ferns GA. Gut microbiome and metabolic syndrome. Diabetes Metab Syndr 2016; 10:504-517.
26. Rameshmad R, Razavi BM, Ferns GA, Hosseinzadeh H. Pharmacology of dipeptidyl peptidase-4 inhibitors and its use in the management of metabolic syndrome: a comprehensive review on drug repositioning. Daru 2019; 27:341-360.
27. Cheang JY, Moyle PM. Glucagon-like peptide-1 (GLP-1)-based therapeutics: Current status and future opportunities beyond type 2 diabetes. Asian Biomed 2018; 13:662-671.
28. Tomlinson B, Hu M, Zhang Y, Chan P, Liu ZM. An overview of new GLP-1 receptor agonists for type 2 diabetes. Expert Opin Investig Drugs 2016; 25:145-158.
29. Meier J. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012; 8:728-742.
30. Tuchscherer RM, Thompson AM, Trujillo JM. Semaglutide: The newest once-weekly GLP-1 RA for type 2 diabetes. Ann Pharmacother 2019; 52:1224-1232.
31. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008; 372:1240-1250.
32. Buse JB, Nauck M, Forst T, Sheu WH, Shenouda SK, Heilman CR, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet 2013; 381:117-124.
33. Pratley RE, Nauck MA, Barnett AH, Feinglos MN, O’Malley F, Harman-Boehm I, et al. Once-weekly albiglutide versus once-daily lixisenatide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol 2014; 2:289-297.
34. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374:39-47.
35. Rosenstock J, Raccah D, Koranyi L, Maffei L, Boka G, Miassess P, et al. Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomised, open-label, active-controlled study (GetGoal-X). Diabetes Care 2013; 36:2945-2951.
36. Dungan KM, Povedano ST, Forst T, Gonzalez JG, Atico S, Sealls W, et al. Once-weekly dulaglutide versus once-daily lixisenatide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet 2014; 384:1349-1357.
37. Shi FH, Li H, Cui M, Zhang ZL, Gu ZC, Liu XY. Efficacy and safety of once-daily semaglutide for the treatment of type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Front Pharmacol 2018; 9:576.
38. Koole C, Wootten D, Simms J, Valant C, Miller LJ, et al. Liraglutide once weekly versus exenatide once daily (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet Diabetes Endocrinol 2018; 6:458-469.
39. Tokuyama Y, Matsui K, Egashira T, Nozaki O, Ishizuka M, et al. Effects of GLP-1 receptor agonists on glucose, gut microbiome and metabolic syndrome. Diabetes Metab Syndr 2017; 11:S561-S566.
40. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112:2735-2752.
41. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112:2735-2752.
42. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112:2735-2752.
33:2074-2076.
41. de Luis DA, Diaz Soto G, Izaola O, Romero E. Evaluation of weight loss and metabolic changes in diabetic patients treated with liraglutide, effect of RS 6923761 gene variant of glucagon-like peptide 1 receptor. J Diabetes Complications 2015; 29:59-59E.
42. Tran KL, Park VI, Pandya S, Muliyil NJ, Jensen BD, Huynh K, et al. Overview of glucagon-like-peptide-1 receptor agonists for the treatment of patients with type 2 diabetes. Am Health Drug Benefits 2017; 10:178-188.
43. Andersen A, Lund A, Knop FK, Vilsbøll T. Glucagon-like peptide 1 in health and disease. Nat Rev Endocrinol 2018; 14:390-403.
44. Doggrell SA. Sgagamultide in type 2 diabetes – is it the best glucagon-like peptide-1 receptor agonist (GLP-1R agonist)? Expert Opin Drug Metab Toxicol 2018; 14:371-377.
45. Hurren KM, Pinelli NR. Drug-drug interactions with glucagon-like peptide-1 receptor agonists. Ann Pharmacother 2012; 46:710-717.
46. Tang Y, Chen XS, Zhang YQ, Zhao WG, Zhang B. Interaction between warfarin and exenatide of one diabetic patient complicated with atrial fibrillation. Chin Pharm J 2017; 52:420-423.
47. Malm-Erjefalt M, Ekblom M, Vouis J, Zdravkovic M, Lundbom N, Kaprio J, et al. GLP-1 response to oral glucose is reduced in prediabetes, screen-detected type 2 diabetes, and obesity and insulin resistance. J Obes Metabol 2010; 12:891-899.
48. Srikanta S, Deedwania P. Management of dyslipidemia in patients with hypertension, diabetes, and metabolic syndrome. Curr Hypertens Rep 2016; 18:76.
49. De Mello AH, Prá M, Cardoso LC, De Bon G, Schäufel N. Effect on the gastrointestinal absorption of drugs from different classes in the biopharmaceutics classification system, when treating with liraglutide. Mol Pharm 2015; 12:4166-4173.
50. Heppner KM, Perez-Tilve D. GLP-1 based therapeutics: Simultaneously combating T2DM and obesity. Front Neurosci 2016; 92.
51. Zoicas F, Droste M, Mayr B, Buchfelder M, Schöfl C. GLP-1 receptor agonist in the treatment for hypothalamic obesity - GLP-1 and obesity. Expert Opin Emerg Med 2014; 15:2487-2500.
52. Eissa H, Boshra V, El-Beltagi HM, Ghanam DM, Saad MAA. Hepatic adenylate cyclase 3 is upregulated by Liraglutide and subsequently plays a protective role in insulin resistance and obesity. Nutr Diabetes 2016; 6:e191.
53. Kim SJ, Nian C, Karunakaran S, Clee SM, Isales CM, McIntosh CHS. GIP-Overexpressing mice demonstrate reduced diet-induced obesity and steatosis, and improved glucose homeostasis. PLoS ONE 2012; 7:e40156.
54. Liu J, Hu Y, Zhang H, Xu Y, Wang G. Exenatide treatment resistance. Diabetes Care 2014; 37:242-251.
55. Ceperuelo-Mallafré V, Duran X, Pachón G, Roche K, Díaz-Blanco L, Vilarrasa N, et al. GLP-1 analogue exenatide inhibits weight loss and metabolic changes in diabetic patients treated with liraglutide, effect of RS 6923761 gene variant of glucagon-like peptide-1 receptor. J Diabetes Complications 2015; 9:92.
56. Samson SL, Sathyarayana P, Jogi M, Gonzalez EV, Gutierrez A, Krishnamurthy R, et al. Exenatide decreases hepatic fibrolast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. Diabetologia 2011; 54:3093-3100.
57. Tashiro Y, Sato K, Watanabe T, Nohtomi K, Terasaki IA, Wilding JP, Daousi C. A glucagon-like peptide-1 analog, liraglutide, delays the onset of diabetes and lowers triglycerides in UCD-T2DM rats. Diabetes 2010; 59:2653-2661.
58. Vinué Á, Navarro J, Herrero-Cervera A, García-Cubas M, Nagashima M. Liraglutide delays the onset of diabetes and lowers triglycerides in UCD-T2DM rats. Diabetes 2010; 59:2653-2661.
59. Faerch K, Torekov SS, Vistensen D, Johansen NB, Witte DR, Løken S, et al. Exenatide decreases hepatic fibrolast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. Diabetologia 2011; 54:3093-3100.
patients with hypothalamic obesity. Obesity 2016; 24:1222-1225.
76. Folli F, Mendoza RG. Potential use of exenatide for the treatment of obesity. Expert Opin Investig Drugs 2011; 20:1717-1722.
77. Nayak UA, Govindan J, Baskar V, Kalupahana D, Singh BM. Exenatide therapy in insulin-treated type 2 diabetes and obesity. QJM 2010; 103:687-694.
78. Doutour A, Abdesselam I, Ancel P, Kober F, Mrad G, Darmon P, et al. Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy. Diabetes Obes Metab 2016; 18:892-891.
79. Acosta A, Camilleri M, Burton D, O’Neill J, Eckert D, Carlson P, et al. Exenatide in obesity with accelerated gastric emptying: a randomized, pharmacodynamics study. Physiol Rep 2015; 3:e12610.
80. Lee HJ, Lee J0, Kim N, Kim JK, Kim HI, Lee YW, et al. Irisin, a novel myokine, regulates glucose uptake in skeletal muscle cells via AMPK. Mol Endocrinol 2015; 29:873-881.
81. Wang X, Chen J, Li L, Zhu CL, Gao J, Rampersad S, et al. New association of bone morphogenetic protein 4 concentrations with fat distribution in obesity and Exenatide intervention on it. Lipids Health Dis 2017; 16:70.
82. Clements JN, Shealy KM. Liraglutide: An injectable option for the management of obesity. Ann Pharmacother 2015; 49:938-944.
83. Blackman A, Foster GD, Zammit G, Rosenberg R, Aronne L, Wadden TA, et al. Effects of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: The scale sleep apnea randomized clinical trial. Int J Obes 2016; 40:1310-1319.
84. Perna S, Guido D, Bologna C, Solerte SB, Guerriero F, Isu A, et al. Liraglutide and obesity in elderly: efficacy in fat loss and safety in order to prevent sarcopenia. A perspective case series study. Aging Clin Exp Res 2016; 28:1251-1257.
85. Hermansen K, Baedal TA, Duering M, Pietraszek A, Mortensen LS, Jorgensen H, et al. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, cross-over trial. Diabetes Obes Metab 2013; 15:1040-1048.
86. Danne T, Bieter T, Kapitze K, Jacobsen SH, Jacobsen LV, Petri KCC, et al. Liraglutide in an adolescent population with obesity: A randomized, double-blind, placebo-controlled 5-week trial to assess safety, tolerability, and pharmacokinetics of liraglutide in adolescents aged 12-17 years. J Paediatr 2017; 181:146-153.e143.
87. Curtis L, Holt H, Richardson T, Knott J, Partridge H. GLP-1 analogue use in patients with sub-optimally controlled type 1 diabetes or obesity improves weight and HbA1c. Pract Diabetes 2016; 33:13-17.
88. Shi L, Zhu J, Yang P, Tang X, Yu W, Pan C, et al. Comparison of exenatide and acarbose on intra-abdominal fat content in patients with obesity and type-2 diabetes: A randomized controlled trial. Obes Res Clin Pract 2017; 11:607-615.
89. Quan H, Zhang H, Wei W, Fang T, Liu J, et al. Gender-related differences in the effects of a combined therapy of Exenatide and Metformin on effects of a long-acting GLP-1 receptor agonist on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis. Diabetes Res Clin Pract 2015; 110:26-37.
90. Liu Q, Adams L, Broyde A, Fernandez R, Baron AD, Parkes DG. The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats. Cardiovasc Diabetol 2010; 9:32.
91. Hoang V, Bi J, Mohankumar SM, Vyas AK. Liraglutide improves hypertension and metabolic perturbation in a rat model of polycystic ovarian syndrome. PLoS ONE 2015; 10:e0126119.
92. Lee MY, Tsai KB, Hsu JH, Shin SJ, Wu JR, Yeh JL. Liraglutide prevents and reverses monocrotaline-induced pulmonary arterial hypertension by suppressing ET-1 and enhancing eNOS/sGC/PKG pathways. Sci Rep 2016; 6:31788.
93. Kim M, Platt MJ, Shibasaki T, Quaggine SE, Backx PH, Seino S, et al. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med 2013; 19:567-575.
94. Gill A, Hoogwerf BJ, Burger J, Bruce S, MacConell L, Yan P, et al. Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: A double-blind, placebo-controlled, randomized pilot study. Cardiovasc Diabetol 2010; 9:6.
95. Okerson T, Yan P, Stonehouse A, Brodows R. Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. Am J Hypertens 2010; 23:334-339.
96. Gustavson SM, Chen D, Somayaj V, Hudson K, Baltrukonis DJ, Singh J, et al. Effects of a long-acting GLP-1 mimetic (PF-4063629) on pulse rate and diastolic blood pressure in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2011; 13:1056-1058.
97. Vanis L, Gentilcore D, Rayner CK, Wishart JM, Horowitz M, Feinle-Bisset C, et al. Effects of small intestinal glucose load on blood pressure, splanchic blood flow, glycemia, and GLP-1 release in healthy older subjects. Am J Physiol Regul Integr Comp Physiol 2011; 300:1524-1531.
98. Yang W, Chen L, Ji Q, Liu X, Ma J, Tandon N, et al. Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: A 16-week randomized, double-blind, active control trial. Diabetes Obes Metab 2011; 13:81-88.
99. Paul S, Best J, Klein K, Han J, Maggs D. Effects of HbA1c and weight reduction on blood pressure in patients with type 2 diabetes mellitus treated with exenatide. Diabetes Obes Metab 2012; 14:826-834.
100. Katout M, Zhu H, Rutsky J, Shah P, Brook RD, Zhong J, et al. Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: Results of a systematic meta-analysis and meta-regression. Am J Hypertens 2014; 27:130-139.
101. Wang B, Zhong J, Lin H, Zhao Z, Yan Z, He, et al. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: A meta-analysis of clinical trials. Diabetes Obes Metab 2013; 15:737-749.
102. Robinson LE, Holt TA, Rees K, Randeva HS, O’Hare JP. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: Systematic review and meta-analysis. BMJ Open 2013; 3:e001986.
103. Fonseca VA, Devries JH, Henry RR, Donsmark M, Thomsen HF, Plutzky J. Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: Insights from a patient-level pooled analysis of six randomized clinical trials. J Diabetes Complications 2014; 28:399-405.
108. Hiramatsu T, Ozeki A, Asai K, Saka M, Hobo A, Furuta S. Liraglutide improves glycemic and blood pressure control and ameliorates progression of left ventricular hypertrophy in patients with type 2 diabetes mellitus on peritoneal dialysis. Ther Apher 2015; 19:598-605.

109. Rondinelli M, Rossi A, Gandolfi A, Saponaro F, Bucciarelli L, Adda G, et al. Use of liraglutide in the real world and impact at 36 months on metabolic control, weight, lipid profile, blood pressure, heart rate, and renal function. Clin Ther 2017; 39:159-169.

110. Nielsen R, Jorsal A, Iversen P, Tolbod LP, Bouchelouche K, Sørensen J, et al. Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE substudy. J Nucl Cardiol 2019; 26:585-597.

111. Kumarruthurai P, Anholm C, Fabricius-Bjerre A, Nielsen OW, Kristiansen O, Madsbad S, et al. Effects of the glucagon-like peptide-1 receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease: A randomized, double-blind, placebo-controlled, crossover study. J Hypertens 2017; 35:1070-1078.

112. Ferdinand KC, White WB, Calhoun DA, Lonn EM, Sager HA, Wang T, et al. Effect of once-weekly dulaglutide on glycated hemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline hemoglobin A1c. Diabetes Obes Metab 2018; 20:409-418.

113. Thazhath SS, Marathe CS, Wu T, Chang J, Kho J, Kuo P, et al. Acute effects of the glucagon-like peptide-1 receptor agonist, exenatide, on blood pressure and heart rate responses to intraduodenal glucose infusion in type 2 diabetes. Diab Vasc Dis Res 2017; 14:59-63.

114. Waldrop G, Zhong J, Peters M, Goud A, Chen YH, Davis SN, et al. Incretin-based therapy in type 2 diabetes mellitus. Hypertension 2014; 64:731-737.

115. Moreira RO, Cobas R, Coelho RCLA. Combination of basal insulin and GLP-1 receptor agonist: Is this the end of basal insulin alone in the treatment of type 2 diabetes mellitus? J Diabetes Complications 2018; 32:113-122.

116. Miao X, Gu Z, Liu Y, Jin M, Lu Y, Gong Y, et al. The glucagon-like peptide-1 analogue liraglutide promotes autophagy through the modulation of 5′-AMP-activated protein kinase in INS-1 β-cells under high glucose conditions. Peptides 2018; 100:127-139.

117. Tran S, Kramer CK, Zimman B, Choi H, Retnakaran R. Effect of chronic liraglutide therapy and its withdrawal on time to postchallenge peak glucose in type 2 diabetes. Am J Physiol Endocrinol Metab 2018; 314:E287-E295.

118. Petit JM, Cercueil JP, Loffroy R, Denimal D, Bouillet B, Fournmont C, et al. Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: The Lira-NAFLD study. J Clin Endocrinol Metab 2017; 102:407-415.

119. Morgan CL, Qiao Q, Grady S, Johnsson K, Jenkins-Jones S, Helden S, et al. Glucose control and weight change associated with treatment with exenatide compared with basal insulin: A retrospective study. Diabetes Ther 2018; 9:269-283.

120. Frias JP, Nakhe S, Ruggles JA, Zhuplatov S, Klein E, Zhou R, et al. Exenatide once weekly improved 24-hour glucose control and reduced glycemic variability in metformin-treated participants with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab 2017; 19:40-48.

121. Voronova V, Zhudenkov K, Penland RC, Boulton DW, Helmlinger G, Peskov K. Exenatide effects on gastric emptying rate and the glucose rate of appearance in plasma: A quantitative assessment using an integrative systems pharmacology model. Diabetes Obes Metab 2018; 20:2034-2038.

122. Hjerpested JB, Flint A, Brooks A, Axelsen MB, Krist T, Blundell J. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obes Metab 2018; 20:610-619.

123. Fleischmann H, Göke R, Bramlage P. Addition of once daily prandial lixisenatide to basal insulin therapy in patients with type-2 diabetes results in a reduction of HbA1c as an effect of postprandial glucose lowering. Diabetes Metab Syndr 2017; 11:S91-S97.

124. Yajima T, Yajima K, Hayashi M, Takahashi H, Yasuda K. Improved glycemic control with once-weekly dulaglutide in addition to insulin therapy in type 2 diabetes mellitus patients on hemodialysis evaluated by continuous glucose monitoring. J Diabetes Complications 2018; 32:310-315.

125. Gallwitz B, Dagogo-Jack S, Thieu V, García-Pérez LE, Pavo M, Saayman R, et al. Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c. Diabetes Obes Metab 2018; 20:409-418.

126. Sedman T, Vasar E, Volke V. Tolerance does not develop toward liraglutide’s glucose-lowering effect. J Clin Endocrinol Metab 2017; 102:2335-2339.

127. Saklayen MG. The global epidemic of the metabolic syndrome. Curr Hypertens Rep 2018; 20:12.

128. Xue H, Li J, Xi E, Wang Y. Role of adaptive reprogramming in the progression of disease. Mol Genet Genomics 2018; 399:1-18.

129. Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov 2019; 18:41-58.